Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 16 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017.
- 23 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Mar 2015 Planned initiation date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov